CN100409762C - Konjaku flour suitable for diabetes - Google Patents
Konjaku flour suitable for diabetes Download PDFInfo
- Publication number
- CN100409762C CN100409762C CNB2006101508280A CN200610150828A CN100409762C CN 100409762 C CN100409762 C CN 100409762C CN B2006101508280 A CNB2006101508280 A CN B2006101508280A CN 200610150828 A CN200610150828 A CN 200610150828A CN 100409762 C CN100409762 C CN 100409762C
- Authority
- CN
- China
- Prior art keywords
- parts
- chromium
- diabetes
- portions
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a konjak flour suitable for human group with diabetes. Its composition includes (by weight portion) 1000-1400 portions of curcumin, 0.32-0.37 portion of methylpyridine chrome, 27-31 portions of zinc glycinate, 245-255 portions of magnesium sulfate, 850-950 portions of calcium carbonate and 27000-28000 portions of konjak flour. Said invention not only has rich nutrients, but also can be used for regulating blood sugar.
Description
Technical field
The present invention relates to a kind of konjaku flour.
Background technology
Diabetes (diabetes mellitus) are one group of clinical syndromes that is caused by the h and E factor interaction, absolute or relative deficiency and target tissue cell reduce insulin sensitivity because of insulin secretion, cause a series of metabolic disorders such as sugar, protein, power and water Xie Zhi.Clinical is main common sign with the hyperglycaemia, and prolonged illness can cause the multisystem grievous injury and threat to life.Clinical IDD (IDDM, I type) and the adult-onset diabetes (NIDDM, II type) of being divided into of diabetes.Diabetic's diet is subject to many limitations because of ill, and the food that is fit to patients with diabetes mellitus at present all is sugarfree foods, does not also have to be fit to diabetic and the edible food of hyperglycemia population by regulating blood sugar level.
Summary of the invention
The objective of the invention is in order to solve the food that is fit to patients with diabetes mellitus at present all is sugarfree foods, also do not have and can be fit to the defective of the edible food of diabetic and hyperglycemia population by regulating blood sugar level, and the konjaku flour that a kind of suitable hyperglycemia population that provides eats.Being fit to the edible konjaku flour of hyperglycemia population is made up of 1000～1400 parts of curcumins, 0.32～0.37 part of methylpyridine chromium, 27～31 parts of glycine zines, 245～255 parts of magnesium sulfate, 850～950 parts of calcium carbonate and 27000～28000 portions of konjaku flours by ratio of weight and the number of copies.The present invention is fit to the diabetic and hyperglycemia population is edible, the blood sugar level of regulating the eater when supplementing the nutrients.The present invention is fit to the konjaku flour of patients with diabetes mellitus and is made up of safe and reliable raw-food material, has no side effect.
The specific embodiment
The specific embodiment one: present embodiment is fit to the edible konjaku flour of hyperglycemia population and is made up of 1000～1400 parts of curcumins, 0.32～0.37 part of methylpyridine chromium, 27～31 parts of glycine zines, 245～255 parts of magnesium sulfate, 850～950 parts of calcium carbonate and 27000～28000 portions of konjaku flours by ratio of weight and the number of copies.
Component suggestion hyperglycemia population according to present embodiment is taken present embodiment konjaku flour 30g every day, divides secondary to take, and available temperature boiling water dashes food.
Curcumin (Curcumin) is a kind of low-molecular-weight natural polyphenol compounds that extracts from the rhizome of Zingiber turmeric (Curcuma Longa) plant turmeric, curcuma zedoary, root tuber of aromatic turmeric etc., it is the main component of food coloring, it is vivid as natural food Agent good stability, strong coloring force, color and luster, be the good food additives that use is recommended by the Committee of Experts of FAO (Food and Agriculture Organization of the United Nation) and the World Health Organization (FAO/WHO), national governments all ratify to use.Curcumin is the medicine food dual purpose plant chemicals, has effects such as anti-inflammatory, antitumor, anti-oxidant and reducing blood lipid as medicine.Inflammation and oxidative stress and diabetes and complication thereof are closely related, discover that curcumin is by anti-inflammatory with anti-oxidant diabetes and complication thereof are had certain therapeutic action.
The curcumin zoopery:
Blood sugar is existed greater than 16.7mmol/L and glucose in urine +++above rat is divided into two groups at random, and first group of diabetes rat freely drunk water and ingest every day, and irritates stomach with the curcumin of 200mg/kg; Second group of diabetes rat freely drunk water and ingest every day.Find in the experimentation that first group of diabetes rat amount of drinking water, food-intake, urine measures all less than second group of diabetes rat, the effectively diabetes-alleviating rat symptom of drinking diuresis of curcumin is described more.
Trivalent chromium is one of essential trace element of human body, as far back as 1969 just the someone find that 3 valency chromium safeguard in the normal glucose metabolic process to have important effect as the confactor of insulin at body.Studies have shown that further the GTF of being made up of several amino acids and 3 valency chromium has the glycometabolic function of the body of adjusting, can reach the effect of improving blood sugar concentration by increasing approach such as glucose oxidase, the generation of promotion glycogen.Clinical research was found 13 diabetes patient's meal supplement every day chromium after 2～4 months, and fasting blood-glucose has obtained tangible improvement.And a diabetic who accepts the treatment of 50 units of insulin every day can make the needs of exogenous insulin reduce to zero after mending chromium.Even to part diabetes patient in late period, behind the additional methyl chromium, its sugar tolerance and glycosylated hemoglobin situation also can take a turn for the better rapidly.32 routine type ii diabetes patients' benefit chromium effect observation is found that the hypoglycemic effect of chromium also is better than general antidiabetic drug.Chromium is except that having tangible blood sugar reducing function, and hypoglycemic experimenter also can correct its hypoglycemia symptom (knock and sleep, eye-blurred, tremble and excessively perspire) by mending chromium.Methylpyridine chromium stability is strong, has fat-solublely, can directly act on histocyte by cell membrane smoothly, is the Organic Chromium that the most easily is absorbed by the body at present.
The chromium zoopery:
Select the healthy male Wistar rat of body weight 180～220g, observe a week after, be divided into 3 groups of ad libs at random and fed for 6 weeks, control group gives basal feed, high fat group gives high lipid food, mends the chromium group and gives high lipid food+chromium (the chromium addition is 0.01167 ‰).Tested for the 6th weekend and put to death Wistar rat (the Wistar rat is put to death preceding 12h on an empty stomach) with etherization, arterial blood extracting detects Wistar rat insulin and blood sugar.Table 1 is a blood glucose value of respectively organizing the Wistar rat, the blood sugar of respectively organizing the Wistar rat when data showed for the 1st, 2 weeks in the table 1 does not have significant difference (P＞0.05), blood glucose value of passing each group in time all is and increases trend, and the blood glucose value of high fat group is higher than control group (P＜0.05) when the 4th, 5 weeks; And since the blood glucose value of benefit chromium group just there is the trend that is lower than high fat group first week, from the 3rd week just being starkly lower than high fat group (P＜0.05), benefit chromium group is tested the 3rd all blood glucose values and is starkly lower than control group (P＜0.05), and the 4th week is close with the control group blood glucose value with the 5th week.Experimental data explanation chromium has the effect that reduces blood sugar.
Table 1 (blood sugar unit is mmol/L)
| Group | The 1st week | The 2nd week | The 3rd week | The 4th week | The 5th week |
| High fat group | 3.59±0.63 | 3.75±0.65 | 4.14±0.69 | 4.94±0.47 | 4.98±0.23 |
| Mend the chromium group | 3.21±0.31 | 3.38±0.23 | 3.57±0.34 | 4.31±0.26 | 4.22±0.32 |
| Control group | 3.60±0.59 | 3.76±0.63 | 4.07±0.29 | 4.18±0.36 | 4.25±0.39 |
Table 2 is respectively to organize insulin level in the Wistar rat blood, and each is organized the insulin value and passes in time all to be and increase trend, and since the insulin level of high fat group just be significantly higher than control group (P＜0.05) in the 1st week; Mend the chromium group since the 3rd all control groups (P＜0.05) that also is significantly higher than, but since the insulin level of benefit chromium group significantly be lower than high fat control group (P＜0.05) in the 3rd week.The interpolation of experimental data explanation chromium can obviously reduce the insulin level in the blood.
Table 2 (insulin units is μ IU/mL)
| Group | The 1st week | The 2nd week | The 3rd week | The 4th week | The 5th week |
| High fat group | 4.7±0.65 | 5.0±0.70 | 7.6±0.74 | 9.0±0.92 | 9.8±1.04 |
| Mend the chromium group | 4.6±0.48 | 4.8±0.47 | 5.1±0.56 | 6.1±0.66 | 7.0±0.68 |
| Control group | 4.0±0.51 | 4.2±0.47 | 4.2±0.48 | 4.8±0.45 | 4.8±0.57 |
Calcium is the abundantest inorganic elements of content in the human body, has physiological action widely.Dietary calcium is by suppressing 1,25-(OH)
2Calcium such as-D3 and thyroid hormone trophic hormone is regulated the endocellular liberation calcium ion concentration, reduces and suffers from hypertension, diabetes and fat risk.Intracellular calcium concentration is the primary signal that insulin discharges, and the high calcium meals can make intracellular calcium concentration reduce, and causes insulin secretion to reduce, and obviously improves hyperinsulinemia.Calcium carbonate edible safety height, wherein calcium constituent accounts for 40% of total molecular weight, so the actual absorption rate of calcium is higher than other calcareous material.
Magnesium ion is second ion that enriches in the cell, is a critical confactor of many enzyme reactions.Magnesium ion has been brought into play second messenger's effect in the activity of insulin, and insulin itself is exactly the important adjusting factor that magnesium is assembled in the cell.Magnesium ion concentration decline may make replying of insulin and active impaired in cell, continues the raising that Mg supplementation then is of value to type ii diabetes people beta Cell of islet respond and insulin active.Magnesium sulfate is the first-selection by diet Mg supplementation ion.
Insulin is unique hypoglycemic hormone in the body, contains 4 metallic atom zinc in its molecular configuration, and it is zinc that 0.5% composition is arranged in the insulin of crystallization approximately, so zinc and insulin exists close getting in touch, and has brought into play important function in the activity of insulin.Zinc can improve the stability of insulin, and promotes that by activating protaminase proinsulin is converted into insulin, so zinc deficiency reduces with insulin secretion and insulin resistance is relevant.Replenish zinc, glucose does not tolerate phenomenon and can be eased.Glycine zine is good absorbing effect, safe in enteron aisle, is the first-selection that diet replenishes zinc.
Konjaku is a kind of herbaceos perennial, has loose poison, beauty treatment, promotes blood circulation, step-down, fat-reducing, appetizing etc. are multi-functional.Content of starch is 35% in the konjaku, and mineral matter element such as protein content is 3%, multivitamin and potassium, phosphorus, selenium and content reach the SKGM (glucomannan) more than 45%.Glucomannan is rich in food fiber, several amino acids and trace element, to reducing cholesterol, preventing and treating hypertension and prevent and treat diabetes certain effect is arranged.
Therefore it is edible that present embodiment is selected curcumin, methylpyridine chromium, glycine zine, magnesium sulfate, calcium carbonate and konjaku flour combination for use, can regulate the blood sugar of hyperglycemia population when supplementing the nutrients effectively by diet.
The specific embodiment two: the difference of the present embodiment and the specific embodiment one is: be fit to the edible konjaku flour of hyperglycemia population and be made up of 1100～1300 parts of curcumins, 0.33～0.36 part of methylpyridine chromium, 28～30 parts of glycine zines, 246～254 parts of magnesium sulfate, 860～940 parts of calcium carbonate and 27200～27800 portions of konjaku flours by ratio of weight and the number of copies.
The specific embodiment three: the difference of the present embodiment and the specific embodiment one is: be fit to the edible konjaku flour of hyperglycemia population and be made up of 1150～1250 parts of curcumins, 0.34～0.35 part of methylpyridine chromium, 28～30 parts of glycine zines, 248～252 parts of magnesium sulfate, 880～920 parts of calcium carbonate and 27300～27700 portions of konjaku flours by ratio of weight and the number of copies.
The specific embodiment four: the difference of the present embodiment and the specific embodiment one is: be fit to the edible konjaku flour of hyperglycemia population and be made up of 1200 parts of curcumins, 0.35 part of methylpyridine chromium, 29 parts of glycine zines, 250 parts of magnesium sulfate, 900 parts of calcium carbonate and 27620 portions of konjaku flours by ratio of weight and the number of copies.
Claims (3)
1. be fit to the edible konjaku flour of hyperglycemia population, it is characterized in that forming by 1000～1400 parts of curcumins, 0.32～0.37 part of methylpyridine chromium, 27～31 parts of glycine zines, 245～255 parts of magnesium sulfate, 850～950 parts of calcium carbonate and 27000～28000 portions of konjaku flours by ratio of weight and the number of copies.
2. the konjaku flour that suitable hyperglycemia population according to claim 1 is edible is characterized in that being made up of 1100～1300 parts of curcumins, 0.33～0.36 part of methylpyridine chromium, 28～30 parts of glycine zines, 246～254 parts of magnesium sulfate, 860～940 parts of calcium carbonate and 27200～27800 portions of konjaku flours by ratio of weight and the number of copies.
3. the konjaku flour that suitable hyperglycemia population according to claim 1 is edible is characterized in that being made up of 1200 parts of curcumins, 0.35 part of methylpyridine chromium, 29 parts of glycine zines, 250 parts of magnesium sulfate, 900 parts of calcium carbonate and 27620 portions of konjaku flours by ratio of weight and the number of copies.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101508280A CN100409762C (en) | 2006-09-28 | 2006-09-28 | Konjaku flour suitable for diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101508280A CN100409762C (en) | 2006-09-28 | 2006-09-28 | Konjaku flour suitable for diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1935006A CN1935006A (en) | 2007-03-28 |
| CN100409762C true CN100409762C (en) | 2008-08-13 |
Family
ID=37952890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101508280A Expired - Fee Related CN100409762C (en) | 2006-09-28 | 2006-09-28 | Konjaku flour suitable for diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100409762C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009025315A1 (en) * | 2007-08-21 | 2009-02-26 | Kyowa Hakko Bio Co., Ltd. | Oral preparation for improvement of bioavailability of curcumin |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1736222A (en) * | 2004-08-16 | 2006-02-22 | 中国农业大学 | Blood sugar reducing or keeping milk powder and preparation process thereof |
| CN1813777A (en) * | 2005-02-04 | 2006-08-09 | 宋春光 | Medicine for treating diabetes retina disease |
-
2006
- 2006-09-28 CN CNB2006101508280A patent/CN100409762C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1736222A (en) * | 2004-08-16 | 2006-02-22 | 中国农业大学 | Blood sugar reducing or keeping milk powder and preparation process thereof |
| CN1813777A (en) * | 2005-02-04 | 2006-08-09 | 宋春光 | Medicine for treating diabetes retina disease |
Non-Patent Citations (2)
| Title |
|---|
| 糖尿病与脂代谢紊乱. 庞建华等.《河北医药》，第26卷第4期. 2004 |
| 糖尿病与脂代谢紊乱. 庞建华等.《河北医药》，第26卷第4期. 2004 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1935006A (en) | 2007-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103238897B (en) | Composite plant solid drink suitable for diabetic patients | |
| CN101744170B (en) | Tartary buckwheat eight ingredient porridge suitable for patients with diabetes and preparing method thereof | |
| CN102113648A (en) | Special dietary noodle applicable to people suffering from 'five-high' metabolic syndrome and preparation method thereof | |
| CN106360310A (en) | Composition for dropping after meal blood sugar and application thereof | |
| CN102783636A (en) | Food nutrition supplement for prophylaxis and treatment of diabetes and application thereof | |
| CN102048002A (en) | Dendrobium tea drink and preparation method thereof | |
| CN108813590A (en) | A kind of low GI formula food of suitable diabetic and preparation method thereof | |
| CN102113652A (en) | Special dietary extruded rice applicable to patients suffering from 'five-high' metabolic syndrome and preparation method thereof | |
| CN103431392A (en) | Composite marine food for special dietary uses for diabetics | |
| CN102160616A (en) | Food formula special for patients suffering from diabetes and preparation method thereof | |
| CN107692222A (en) | A kind of Traditional Chinese medicine for decreasing blood sugar dietotherapy is for food product | |
| KR102408480B1 (en) | Composition for treating diabetic disease | |
| CN100409762C (en) | Konjaku flour suitable for diabetes | |
| CN1101133C (en) | Formulation and production process of Baile biscuit with dietary fiber having hypoglycemic function | |
| EP2294932B1 (en) | Carbohydrate mixture and the use thereof for preparing a product for oral or enteral nutrition | |
| CN102204650A (en) | Health staple food with low glycemic index, its preparation method and application in blood sugar reduction | |
| CN109043555A (en) | A kind of Special food and preparation method thereof that hyperglycemic patients are edible | |
| CN100577183C (en) | Lipoic acid health food and application thereof | |
| Mujahid et al. | A combination of bitter gourd ethanolic extract with ant lion larvae aqueous extract for a blood glucose-lowering agent | |
| Laksmitawati et al. | Activity of porang flour and moringa extract to blood glucose and lipid levels in alloxan induced diabetic mice | |
| CN1286503C (en) | A Chinese medicinal composition with blood sugar and blood lipid reducing effects, and its preparation method | |
| CN106262569A (en) | A kind of nutraceutical of three-hypers patient | |
| CN108142784A (en) | A kind of wheat composite flour and preparation method thereof | |
| Santhi Sirisha et al. | Estimation of glycemic index of ragi recipes incorporated with curry leaf powder | |
| Premlata et al. | Role of Vidangadi Kwatha in Madhumeha (Diabetes Mellitus Type II) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080813 Termination date: 20120928 |